Abstract:Minimal residual disease (MRD) is a very important prognostic factor in multiple myeloma (MM). The major types of MRD tests include cellbased test (multiparameter flow cytometry) and molecular tests (including PCR and gene sequencing), and the various techniques have inherent advantages and limitations. In clinical application, MRD negative can significantly prolong progressionfree survival and overall survival of patients who receive hematopoietic stem cell transplantation and conventional chemotherapy. Moreover, the MRD status is of great significance to the selection of treatment options.

Key words:Multiple myeloma,Neoplasm, residual